Management of end-stage sarcoidosis: Pulmonary hypertension and lung transplantation

European Respiratory Journal

Volumn 39, Issue 6, 2012, Pages 1520-1533

  Shlobin, Oksana A ^a   Nathan, Steven D ^a  

^a INOVA FAIRFAX HOSPITAL   (United States)

Author keywords

Lung transplantation; Pulmonary hypertension; Sarcoidosis

Indexed keywords

AMBRISENTAN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AMPHOTERICIN B; BOSENTAN; BRAIN NATRIURETIC PEPTIDE; CYTOKINE; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; NITRIC OXIDE; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; PROSTANOID; SILDENAFIL; VASOACTIVE AGENT; VORICONAZOLE;

6 MINUTE WALKING TEST; BLOOD VESSEL CAPACITANCE; BRONCHIECTASIS; CARDIAC SARCOIDOSIS; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; FIBROSING ALVEOLITIS; GRANULOMA; GRANULOMATOUS INFLAMMATION; HEART CATHETERIZATION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LUNG TRANSPLANTATION; HEART RIGHT VENTRICLE FUNCTION; HEMOPTYSIS; HUMAN; HYPOXEMIA; LUNG ALLOCATION SCORE; LUNG ASPERGILLOSIS; LUNG CAVITY; LUNG FUNCTION; LUNG TRANSPLANTATION; MORTALITY; MYCETOMA; ORGAN TRANSPLANTATION; OXYGEN SATURATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; RIGHT HEART CATHETERIZATION; RIGHT VENTRICULAR SYSTOLIC PRESSURE; SARCOIDOSIS; SCORING SYSTEM; SURVIVAL; THORAX RADIOGRAPHY; THROMBOEMBOLISM; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; VASOCONSTRICTION;

FEMALE; HUMANS; HYPERTENSION, PULMONARY; LUNG TRANSPLANTATION; MALE; NITRIC OXIDE; PHOSPHODIESTERASE INHIBITORS; PROSTAGLANDINS I; SARCOIDOSIS, PULMONARY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84861912157     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00175511     Document Type: Review

References (101)

1. Baughman RP, Teirstein AS, Judson MA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001; 164: 1885-1889.
2. Rybicki BA, Major M, Popovich J Jr, et al. Racial differences in sarcoidosis incidence: a five year study in a health maintenance organization. Am J Epidemiol 1997; 145: 234-241.
3. Iwai K, Sekiguti M, Hosoda Y, et al. Racial differences in cardiac sarcoidosis incidence observed at autopsy. Sarcoidosis 1994; 11: 248-251.
4. Sulica R, Teirstein AS, Kakarla S, et al. Distinctive clinical, radiographic and functional characteristics of patients with sarcoidosis-related pulmonary hypertension. Chest 2005; 128: 1483-1489.
5. Handa T, Nagai S, Miki S, et al. Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. Chest 2006; 129: 1246-1252.
6. Gluskowski J, Hawrylkiewicz I, Zych D, et al. Pulmonary haemodynamics at rest and during exercise in patients with sarcoidosis. Respiration 1984; 46: 26-32.
7. Baughman RP, Engel PJ, Meyer CA, et al. Pulmonary hypertension in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23: 108-116.
8. Shorr AF, Helman DL, Davies DB, et al. Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics. Eur Respir J 2005; 25: 783-788.
9. Simmoneau G, Robbins I, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. JACC 2009; 54: S43-S54.
10. Baughman RP. Pulmonary hypertension associated with sarcoidosis. Arthritis Res Ther 2007; 9: S8.
11. Nunes H, Humbert M, Capron F, et al. Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax 2006; 61: 68-74.
12. Takemura T, Matsui Y, Saiki S, et al. Pulmonary vascular involvement in sarcoidosis: a report of 40 autopsy cases. Hum Pathol 1992; 23: 1216-1223.
13. Corte T, Wells AU, Nicholson AG, et al. Pulmonary hypertension in sarcoidosis: a review. Respirology 2011; 16: 69-77.
14. Damuth TE, Biwer JS, Cho K, et al. Major pulmonary artery stenosis causing pulmonary hypertension in sarcoidosis. Chest 1980; 78: 888-891.
15. Hiffstein V, Ranganathan N, Mullen JBM, et al. Sarcoidosis stimulating pulmonary veno-occlusive disease. Am Rev Respir Dis 1986; 134: 809-811.
16. Portier F, Lerebourg-Pigeonnaiere G, Thiberville L, et al. Sarcoidosis simulating pulmonary veno-occlusive disease. Rev Mal Respir 1991; 8: 101-102.
17. Toonkel RL, Borczuk AC, Pearson GD, et al. Sarcoidosis-associated fibrosing mediastinitis with resultant pulmonary hypertension: a case report and review of literature. Respiration 2009; 79: 341-345.
18. Smith LJ, Lawrence JB, Katzenstein AL. Vascular sarcoidosis: a rare case report of pulmonary hypertension. Am J Med Sci 1983; 285: 38-44.
19. Rosen Y, Moon S, Huang CT, et al. Granulomatous pulmonary angiitis in sarcoidosis. Arch Pathol Lab Med 1977; 101: 170-174.
20. Thannickal VJ, Toews GB, White ES, et al. Mechanisms of pulmonary fibrosis. Annu Rev Med 2004; 55: 395-417.
21. Mahapatra S, Nishimura RA, Sorajja P, et al. Relationship of pulmonary arterial capacitance and mortality in idiopathic pulmonary arterial hypertension. J Am Coll Cardiol 2006; 47: 799-803.
22. Galie N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res 2004; 61: 227-237.
23. Terashita K, Kato S, Sata M, et al. Increased endothelin-1 levels of BAL fluid in patients with pulmonary sarcoidosis. Respirology 2006; 11: 145-151.
24. Letizia C, Danese A, Reale MG, et al. Plasma levbels of endothelin-1 increase in patients with sarcoidosis and fall after disease remission. Panminerva Med 2001; 43: 257-261.
25. Sutendra G, Dromparis P, Bonnet S, et al. Pyruvate dehydrogenase inhibition by the inflammatory cytokine TNF α contributes to the pathogenesis of pulmonary aterial hypertension. J Mol Med 2011; 89: 771-783.
26. Chen ES, Moller DR. Sarcoidosis - scientific progress and clinical challenges. Nature Rev Rheumatol 2011; 7: 457-467.
27. Preston IR, Klinger JR, Landzberg MJ, et al. Vasoresponsivness of sarcoid-associated pulmonary hypertension. Chest 2001; 120: 866-872.
28. Barst RJ, Ratner SJ. Sarcoidosis and Reactive Pulmonary Hypertension. Arch Intern Med 1985; 145: 2112-2114.
29. Bargout R, Kelly RF. Sarcoid heart disease: clinical course and treatment. Int J Cardiology 2004; 97: 173-182.
30. Baughman RP, Engel PJ, Taylor L, et al. Survival in sarcoidosis associated pulmonary hypertension: the importance of hemodynamic evaluation. Chest 2010; 138: 1078-1085.
31. Salazaar A, Mana J, Sala J, et al. Combined portal and pulmonary hypertension in sarcoidosis. Respiration 1994; 61: 517-520.
32. Turner GA, Lower EE, Corser BC, et al. Sleep apnea in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1997; 14: 61-64.
33. Swigris JJ, Olson AL, Huie TJ, et al. Increased risk of pulmonary embolism among US decedents with sarcoidosis from 1988 to 2007. Chest 2011; 140: 1261-1266.
34. Crawshaw AP, Wotton CJ, Yeates DG, et al. Evidence for association between sarcoidosis and pulmonary embolism from 35-year record linkage study. Thorax 2011; 66: 447-448.
35. Shorr AF, Davies DB, Nathan SD. Predicting mortality in patients with sarcoidosis awaiting lung transplantation. Chest 2003; 124: 922-928.
36. Arcasoy SM, Christie JD, Pochettino A, et al. Characteristics and outcomes of patients with sarcoidosis listed for lung transplantation. Chest 2001; 120: 873-880.
37. Diaz-Guzman E, Farver C, Parambil J, et al. Pulmonary hypertension caused by sarcoidosis. Clin Chest Med 2008; 29: 549-566.
38. Leuchte HH, Baumgartner RA, Nounou ME, et al. Brain natriuretic peptide is a prognostic parameter in chronic lung diseases. Am J Respir Crit Care Med 2006; 173: 744-750.
39. Corte TJ, Wort SJ, Gatzoulis MA, et al. Elevated brain natriuretic peptide predicts mortality in interstitial lung disease. Eur Respir J 2010; 36: 819-825.
40. Handa T, Nagai S, Ueda S, et al. Significance of plasma NT-preBNP levels as a biomarker in the assessment of cardiac involvement and pulmonary hypertension in patients with sarcoidosis. Sarcoidosis Vasc Diffuce Lung Dis 2010; 27: 27-35.
41. Bourbonnais JM, Samavati L. Clinical predictors of pulmonary hypertension in sarcoidosis. Eur Respir J 2008; 32: 296-302.
42. Baughman RP, Sparkman BK, Lower EE. Six minute walk test and health status assessment in sarcoidosis. Chest 2007; 132: 207-213.
43. Palmero V, Sulica R. Sarcoidosis-associated pulmonary hypertension: assessment and management. Semin Respir Crit Care Med 2010; 31: 494-500.
44. Alhamad EH, Ahmad Shaik S, Idrees MM, et al. Outcome measures of the 6 minute walk test: relationships with physiologic and computed tomography findings in patients with sarcoidosis. BMC Pulm Med 2010; 10: 42-49.
45. Arcasoy SM, Christie JD, Ferrari VA, et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 2003; 167: 735-740.
46. Rodman DM, Lindenfeld J. Successful treatment of sarcoidosis-associated pulmonary hypertension with corticosteroids. Chest 1990; 97: 500-502.
47. Davies J, Nellen M, Goodwin JF. Reversible pulmonary hypertension in sarcoidosis. Postgrad Med J 1982; 58: 282-285.
48. Gluskowski J, Hawrylkiewicz I, Zych D, et al. Effects of corticosteroid treatment on pulmonary haemodynamics in patients with sarcoidosis. Eur Respir J 1990; 3: 403-407.
49. Diaz-Guzman E, Farver C, Parambil J, et al. Pulmonary hypertension caused by sarcoidosis. Clin Chest Med 2008; 29: 549-571.
50. Baughman RP, Judson MA, Lower EE, et al. Inhaled iloprost for sarcoidosis associated pulmonary hypertension. Sarcoidosis Vasc Diffuse Lung Dis 2009; 26: 110-120.
51. Fisher KA, Serlin DM, Wilson KC, et al. Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment. Chest 2006; 130: 1481-1488.
52. Barnett CF, Bonura EJ, Nathan SD, et al. Treatment of sarcoidosis-associated pulmonary hypertension. A two-center experience. Chest 2009; 135: 1455-1461.
53. Milman N, Burton CM, Iversen M, et al. Pulmonary hypertension in end-stage pulmonary sarcoidosis: therapeutic effect of sildenafil? J Heart Lung Transplant 2008; 75: 329-334.
54. Culver DA, Minai OA, Chapman JT, et al. Treatment of pulmonary hypertension in sarcoidosis. Proc Am Thoracic Soc 2005; 2: A862.
55. Judson MA, Ford HJ, Donohue JF, et al. Ambrisentan for sarcoidosis associated pulmonary hypertension. Am J Respir Crit Care 2010; 181: A2368.
56. Baughman RP. Double Blind, Randomized Trial of Bosentan for Sarcoidosis Associated Pulmonary Hypertension. http://clinicaltrials. gov/ct2/show/ NCT00581607 Date last accessed: May 10, 2011. Date last updated: November 2, 2011.
57. Hertz MI, Aurora P, Christie JD, et al. Scientific Registry of the International Society for Heart and Lung Transplantation: introduction to the 2010 Annual Reports. J Heart Lung Transplant 2010; 29: 1083-1141.
58. Baughman RP, Winger DB, Bowen EH, et al. Predicting respiratory failure in sarcoidosis patients. Sarcoidosis Vasc Diffuse Lung Dis 1997; 14: 154-158.
59. Shorr AF, Davies DD, Nathan SD. Outcomes for patients with sacroidosis awaiting lung transplantation. Chest 2002; 122: 233-238.
60. Orens JB, Estenne M, Arcasoy S, et al. International guidelines for the selection of lung transplant candidates: 2006 update - a consensus report from the pulmonary scientific council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006; 25: 745-755.
61. Egan TM, Murray S, Bustami RT, et al. Development of the new allocation system in the United States. Am J Transplant 2006; 6: 1212-1227.
62. Chen H, Shiboski SC, Golden JA, et al. Impact of the lung allocation score on lung transplantation for pulmonary arterial hypertension. Am J Respir Crit Care Med 2009; 180: 468-474.
63. Iannuzzi MC, Fontana JR. Sarcoidosis: clinical presentation, immunopathogenesis and therapeutics. JAMA 2011; 305: 391-399.
64. Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation 1978; 58: 1204-1211.
65. Mehta D, Lubitz SA, Frankel Z, et al. Cardiac involvement in patients with sarcoidosis: diagnostic and prognostic value of outpatient testing. Chest 2008; 35: 933-941.
66. Patel MR, Cawley PJ, Heitner JF, et al. Detection of myocardial damage in patients with sarcoidosis. Circulation 2009; 120: 1969-1977.
67. Yazake Y, Isobe M, Hiroe M, et al. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol 2001; 88: 1006-1010.
68. Freundlich IM, Libshitz HI, Glassman LM, et al. Sarcoidosis. Typical and atypical thoracic manisfestations. Clin Radiol 1970; 21: 376-383.
69. Wollschlager C, Khan F. Aspergillomas complicating sarcoidosis: a prospective study in 100 patients. Chest 1984; 86: 585-588.
70. Hours S, Nunes H, Kambouchner M, et al. Pulmonary cavitary sarcoidosis. Medicine 2008; 87: 142-151.
71. Gorske K, Fleming RJ. Mycetoma formation in cavitary sarcoidosis. Radiology 1970; 95: 279-285.
72. Dar MA, Ahmad M, Weinstein AJ, et al. Thoracic aspergillosis (Part I): overviewand aspergilloma. Cleve Clin Q 1984; 51: 615-630.
73. Pena T, Soubani AO, Samavati L. Aspergillus lung disease in patients with sarcoidosis: a case series and review of the literature. Lung 2011; 189: 167-172.
74. Hammerman KJ, Christianson CS, Huntington I. Spontaneous lysis of aspergilloma. Chest 1973; 64: 697-699.
75. Nathan SD, Saleeb PG, Saft H, et al. Prevalence and impact of aspergillomas in patients with advanced sarcoidosis. Am J Respir Crit Care Med 2007; 175: A361.
76. Israel HL, Ostrow A. Sarcoidosis and aspergilloma. Am J Med 1969; 47: 243-250.
77. Waldhorn RE, Tsou E, Kerwin DM. Invasive pulmonary aspergillosis associated with aspergilloma in sarcoidosis. South Med J 1983; 76: 251-253.
78. Kaplan J, Johnson Johns C. Mycetomas in pulmonary sarcoidosis: non-surgical management. Johns Hopkins Med J 1979; 145: 157-161.
79. Stevens DA, Kan VL, Judson MA, et al. Practice guidelines for disease caused by aspergillus. Infectious Dis Soc of Amer 2000; 30: 696-709.
80. Sharma OP, Chwogule R. Many faces of pulmonary aspergillosis. Eur Respir J 1998; 12: 705-715.
81. Dannaouli E, Garcia-Hermoso D, Naccache JM, et al. Use of voriconazole in a patient with aspergilloma caused by an itraconazole-resistance strain of Aspergillus fumigatus. J Med Microbiol 2006; 55: 1457-1459.
82. De Beule K, De Doncker P, Cauwenbergh G, et al. The treatment of aspergillosis and aspergilloma with itraconazole, clinical results of an open international study (1982-1987). Mycoses 1988; 31: 476-485.
83. Kravitz JN, Bullington WM, Schabel S, et al. Intracavitary amphotericin B for pulmonary aspergilloma complicated by serious hemoptysis in fibrocystic sarcoidosis. Am J Respir Crit Care 2010; 181: A2951.
84. Kravitz JN, Steed LL, Judson MA. Intracavitary voriconazole for the treatment of hemoptysis complicating Pseudallescheria angusta pulmonary mycetomas in fibrocystic sarcoidosis. Med Mycol 2011; 49: 198-201.
85. Lencher GS, Atkinson GW. Sarcoidosis and aspergilloma. The role of surgery. Chest 1982; 82: 430-432.
86. Gueraa M, Santos N, Miranda J, et al. Surgical management of pulmonary aspergilloma. Rev Port Cir Cardiothorac Vasc 2008; 15: 135-138.
87. Jackson M, Flower CD, Shneerson JM. Treatment of symtpomatic pulmonary aspergillomas with intracavitary instillation of amphotericin B through an indwelling catheter. Thorax 1993; 48: 928-930.
88. Rumbak M, Kohler G, Eastridge C, et al. Topical treatment of life threatening haemoptysis from aspergillomas. Thorax 1996; 51: 253-255.
89. Judson MA. Lung transplantation for pulmonary sarcoidosis. Eur Respir J 1998; 11: 738-744.
90. Hadjiliadis D, Sporn TA, Perfect JR, et al. Outcome of lung transplantation in patientswithmycetomas. Chest 2002; 121: 128-134.
91. Polychronopoulos VS, Prakash UB. Airway involvement in sarcoidosis. Chest 2009; 136: 1371-1380.
92. Akira M, Kozuka T, Inoue Y, et al. Long-term follow-up CT scan evaluation in patients with pulmonary sarcoidosis. Chest 2005; 127: 185-191.
93. Abehsera M, Valeyre D, Grenier P, et al. Sarcoidosis with pulmonary fibrosis: CT patterns and correlation with pulmonary function. Am J Roentgenol 2000; 174: 1751-1757.
94. Rockoff SD, Rohatgi PK. Unusual manifestations of thoracic sarcoidosis. Am J Roentgenol 1985; 144: 513-528.
95. Shah L. Lung transplantation in sarcoidosis. Semin Respir Crit Care Med 2007; 28: 134-140.
96. Shorr AF, Helman DL, Davies DB, et al. Sarcoidosis, race and short-term outcomes following lung transplantation. Chest 2004; 125: 990-996.
97. Nunley DR, Hattler B, Keenan RJ, et al. Lung transplantation for end-stage pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16: 93-100.
98. Wille KM, Gaggar A, Hajari AS, et al. Bronchiolitis obliterans syndrome and survival following lung transplantation for patients with sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2008; 25: 117-124.
99. Milman N, Andersen CD, Burton CM, et al. Recurrent sarcoid granulomas in a transplanted lung derive from recipient immune cells. Eur Respir J 2005; 26: 549-552.
100. Johnson BA, Duncan SR, Ohori NP, et al. Recurrence of sarcoidosis in pulmonary allograft recipients. Am Rev Respir Dis 1993; 148: 1373-1377.
101. Martinez FJ, Orens JB, Deeb M, et al. Recurrence of sarcoidosis following bilateral allogeneic lung transplantation. Chest 1994; 106: 1597-1599.